Back to Newsroom

olero Pharmaceuticals to Present Supportive Preclinical Data for Investigational CDK Inhibitor Alvocidib at European Hematology Association Annual Meeting

SALT LAKE CITY, June 15, 2017 /PRNewswire/ — Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the Company will present preclinical data from its alvocidib program at the European Hematology Association (EHA) 22nd Annual Congress, June 22-25 in Madrid. Alvocidib is an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), which is in Phase II development for the treatment of MCL-1-dependent relapsed/refractory acute myeloid leukemia (AML).